Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 12'th Apr 2026
New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/26/26
New York, New York--(Newsfile Corp. - April 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19,
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
09:30pm, Saturday, 11'th Apr 2026
NEW YORK, April 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and Marc
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
07:34am, Saturday, 11'th Apr 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025 When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026 Basis
SAN FRANCISCO, April 10, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Immun
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and M
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
04:03pm, Friday, 10'th Apr 2026
BENSALEM, Pa., April 10, 2026 /PRNewswire/ -- The Law Offices of Howard G.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
03:55pm, Friday, 10'th Apr 2026
ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress boosting momentum.
SAN DIEGO--(BUSINESS WIRE)---- $IBRX #IBRX--The case alleges ImmunityBio materially overstated Anktiva's capabilities.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:51am, Friday, 10'th Apr 2026
LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityB
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
Berger Montague PC Investigating Claims on Behalf of ImmunityBio, Inc. (IBRX) Investors After Class Action Filing
08:41am, Friday, 10'th Apr 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - April 10, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio
SAN FRANCISCO, April 9, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio
